| FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 R Boellaard, R Delgado-Bolton, WJG Oyen, F Giammarile, K Tatsch, ... European journal of nuclear medicine and molecular imaging 42, 328-354, 2015 | 2773 | 2015 |
| Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma ME Juweid, S Stroobants, OS Hoekstra, FM Mottaghy, M Dietlein, ... Journal of clinical oncology 25 (5), 571-578, 2007 | 1670 | 2007 |
| FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 R Boellaard, MJ O’Doherty, WA Weber, FM Mottaghy, MN Lonsdale, ... European journal of nuclear medicine and molecular imaging 37, 181-200, 2010 | 1576 | 2010 |
| Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial A Engert, H Haverkamp, C Kobe, J Markova, C Renner, A Ho, J Zijlstra, ... The Lancet 379 (9828), 1791-1799, 2012 | 743 | 2012 |
| Treatment of older patients with mantle-cell lymphoma HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ... New England Journal of Medicine 367 (6), 520-531, 2012 | 627 | 2012 |
| Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma M Schaapveld, BMP Aleman, AM van Eggermond, CPM Janus, ADG Krol, ... New England Journal of Medicine 373 (26), 2499-2511, 2015 | 593 | 2015 |
| The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials R Boellaard, WJG Oyen, CJ Hoekstra, OS Hoekstra, EP Visser, ... European journal of nuclear medicine and molecular imaging 35, 2320-2333, 2008 | 445 | 2008 |
| Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes ML De Bruin, J Sparidans, MB van’t Veer, EM Noordijk, MW Louwman, ... J Clin Oncol 27 (26), 4239-4246, 2009 | 428 | 2009 |
| Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial B Von Tresckow, A Plütschow, M Fuchs, B Klimm, J Markova, A Lohri, ... J Clin Oncol 30 (9), 907-913, 2012 | 387 | 2012 |
| PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin … P Borchmann, H Goergen, C Kobe, A Lohri, R Greil, DA Eichenauer, ... The Lancet 390 (10114), 2790-2802, 2017 | 363 | 2017 |
| Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced … C Kobe, M Dietlein, J Franklin, J Markova, A Lohri, H Amthauer, ... Blood, The Journal of the American Society of Hematology 112 (10), 3989-3994, 2008 | 279 | 2008 |
| 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review JM Zijlstra, G Lindauer-van der Werf, OS Hoekstra, L Hooft, PC Huijgens Haematologica 91 (4), 522-529, 2006 | 271 | 2006 |
| Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial N Kalakonda, M Maerevoet, F Cavallo, G Follows, A Goy, JSP Vermaat, ... The Lancet Haematology 7 (7), e511-e522, 2020 | 262 | 2020 |
| Comparison of modern and conventional imaging techniques in establishing multiple myeloma‐related bone disease: a systematic review JC Regelink, MC Minnema, E Terpos, MH Kamphuis, PG Raijmakers, ... British journal of haematology 162 (1), 50-61, 2013 | 254 | 2013 |
| Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non … K Behringer, H Goergen, F Hitz, JM Zijlstra, R Greil, J Markova, S Sasse, ... The Lancet 385 (9976), 1418-1427, 2015 | 219 | 2015 |
| Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial E Vellenga, WLJ van Putten, MB van't Veer, JM Zijlstra, WE Fibbe, ... Blood, The Journal of the American Society of Hematology 111 (2), 537-543, 2008 | 216 | 2008 |
| Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography LR Perk, OJ Visser, M Stigter-van Walsum, MJWD Vosjan, GWM Visser, ... European journal of nuclear medicine and molecular imaging 33, 1337-1345, 2006 | 197 | 2006 |
| Positron emission tomography–guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German … M Fuchs, H Goergen, C Kobe, G Kuhnert, A Lohri, R Greil, S Sasse, ... Journal of clinical oncology 37 (31), 2835-2845, 2019 | 193 | 2019 |
| Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study JEC Bromberg, S Issa, K Bakunina, MC Minnema, T Seute, M Durian, ... The Lancet Oncology 20 (2), 216-228, 2019 | 184 | 2019 |
| Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials? YWS Jauw, CW Menke-van der Houven van Oordt, OS Hoekstra, ... Frontiers in pharmacology 7, 131, 2016 | 165 | 2016 |
